DOI QR코드

DOI QR Code

Correlation between Low Gleason Score and Prostate Specific Antigen Levels with Incidence of Bone Metastases in Prostate Cancer Patients: When to Omit Bone Scans?

  • Sanjaya, I. Putu Gde (Department of Urology, Cipto Mangunkusumo Hospital, University of Indonesia) ;
  • Mochtar, Chaidir Arief (Department of Urology, Cipto Mangunkusumo Hospital, University of Indonesia) ;
  • Umbas, Rainy (Department of Urology, Cipto Mangunkusumo Hospital, University of Indonesia)
  • Published : 2013.09.30

Abstract

Background: To identify correlation and incidence of bone metastases in prostate cancer patient with low Gleason scores (GS) and prostate specific antigen (PSA) levels. Materials and Methods: This descriptive restrospective study covered patients with prostate cancer in Cipto Mangunkusumo Hospital in 2006-2011. Of a total of 478, those who had PSA values, histological examination, and bone scan were included, resulting in 358 eligible cases. PSA values were measured using the sandwich electrochemiluminescent immunoassay. Histological examination was graded according to Gleason's grading system and divided into 3 categories: well differentiated ($GS{\leq}6$), moderately differentiated (GS 7) and poorly differentiated (GS 8-10). Bone scans were performed using a radiopharmaceutical agent ($T_c$ 99m methylenen diphosphonate) with images captured by gamma camera. Results: The mean age was $67.5{\pm}7.8$, mean GS was $7.7{\pm}1.3$ and median PSA was 56.9 (range: 0.48-17000 ng/mL). There were 11 patients (3.0%) with positive bone scan with PSA<20 ng/mL and GS<8. Furthermore, there were 2 patients (0.6%) with $GS{\leq}6$ and PSA<10 ng/mL showing bone metastasis. Conclusions: In our study, there were still small percentage of patients with bone metastasis even when low values of PSA (PSA<10 ng/mL) and GS ($GS{\leq}6$) were applied.

Keywords

Prostate cancer;low PSA;low GS;bone metastases;bone scans

References

  1. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005). The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol, 29, 1228-42. https://doi.org/10.1097/01.pas.0000173646.99337.b1
  2. Akaza H, Carroll P, Cooperberg MR, Hinotsu S (2012). Fifth joint meeting of J-CAP and capsure: advancing the global understanding of prostate cancer and its management. Jpn J Clin Oncol, 42, 226-36. https://doi.org/10.1093/jjco/hyr194
  3. Ataus S, Citci A, Alici B, et al (1999). The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer. Int Urol Nephrol, 31, 481-9. https://doi.org/10.1023/A:1007163227968
  4. Briganti A, Passoni N, Ferrari M, et al (2010). When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol, 57, 551-8. https://doi.org/10.1016/j.eururo.2009.12.023
  5. Bubendorf L, Schopfer A, Wagner U, et al (2000). Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum pathol, 31, 578-83. https://doi.org/10.1053/hp.2000.6698
  6. Center MM, Jemal A, Lortet-Tieulent J, et al (2012). International variation in prostate cancer incidence and mortality rates. Eur Urol, 61, 1079-92. https://doi.org/10.1016/j.eururo.2012.02.054
  7. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  8. Haukaas S, Roervik J, Halvorsen OJ, Foelling M (1997). When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? Br J Urol, 79, 770-6. https://doi.org/10.1046/j.1464-410X.1997.00141.x
  9. Heidenreich A, Aus G, Bolla M, et al (2007). EAU Guidelines on Prostate Cancer. Eur Urol, 53, 68-80.
  10. Ito K, Kubota Y, Suzuki K, et al (2000). Correlation of prostatespecific antigen before prostate cancer detection and clinicopathologic features: evaluation of mass screening populations. Urol, 55, 705-9. https://doi.org/10.1016/S0090-4295(99)00568-3
  11. Jemal A, Center MM, DeSantis C, Ward EM (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19, 1893-907. https://doi.org/10.1158/1055-9965.EPI-10-0437
  12. Kosuda S, Yoshimura I, Aizawa T, et al (2002). Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer, 94, 964-72. https://doi.org/10.1002/cncr.10340
  13. Lai MH, Luk WH, Chan JC (2011). Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: Feasibility in Asian population. Urol Oncol, 29, 275-9. https://doi.org/10.1016/j.urolonc.2009.05.007
  14. Lin K, Szabo Z, Chin BB, Civelek AC (1999). The value of a baseline bone scan in patients with newly diagnosed prostate cancer. Clin Nucl Med, 24, 579-82. https://doi.org/10.1097/00003072-199908000-00007
  15. Mateen FJ, Shinohara RT, Carone M, et al (2012). Neurologic disorders incidence in HIV+ vs HIV- men: Multicenter AIDS Cohort Study, 1996-2011. Neurology, 79, 1873-80. https://doi.org/10.1212/WNL.0b013e318271f7b8
  16. Matsuda T, Saika K (2009). Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. Jpn J Clin Oncol 39, 468-9. https://doi.org/10.1093/jjco/hyp077
  17. McArthur C, McLaughlin G, Meddings RN (2012). Changing the referral criteria for bone scan in newly diagnosed prostate cancer patients. Br J Radiol, 85, 390-4. https://doi.org/10.1259/bjr/79184355
  18. Namiki M, Akaza H, Lee SE, et al (2010). Prostate cancer working group report. Jpn J Clin Oncol, 40, 70-5. https://doi.org/10.1093/jjco/hyq130
  19. Nguyen DX, Bos PD, Massague J (2009). Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer, 9, 274-84. https://doi.org/10.1038/nrc2622
  20. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC (1993). The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA, 269, 57-60. https://doi.org/10.1001/jama.1993.03500010067033
  21. Pal RP, Thiruudaian T, Khan MA (2008). When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer? Asian J Androl, 10, 890-5. https://doi.org/10.1111/j.1745-7262.2008.00427.x
  22. Quinn M, Babb P (2002). Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int, 90, 162-73. https://doi.org/10.1046/j.1464-410X.2002.2822.x
  23. Rudoni M, Antonini G, Favro M, et al (1995). The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med, 22, 207-11. https://doi.org/10.1007/BF01081514
  24. Sadik M, Suurkula M, Hoglund P, Jarund A, Edenbrandt L (2008). Quality of planar whole-body bone scan interpretations-a nationwide survey. Eur J Nucl Med Mol Imaging, 35, 1464-72. https://doi.org/10.1007/s00259-008-0721-5
  25. Wolff JM, Zimny M, Borchers H, et al (1998). Is prostatespecific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol, 33, 376-81. https://doi.org/10.1159/000019619
  26. Yang G, Zuo S, Ma C, et al (2009). The diagnostic correlations of bone scintigraphy, pathological grade and PSA for metastatic prostate cancers. The Chinese-German J Clinical Oncol, 8, 702-4. https://doi.org/10.1007/s10330-009-0150-3
  27. Zaman MU, Fatima N, Sajjad Z (2011). Metastasis on bone scan with low prostate specific antigen (${\leq}$20 ng/ml) and Gleason's score (<8) in newly diagnosed Pakistani males with prostate cancer: should we follow Western guidelines? Asian Pac J Cancer Prev, 12, 1529-32.

Cited by

  1. Feedback on Baseline Use of Staging Images is Important to Improve Image Overuse with Newly Diagnosed Prostate Cancer Patients vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1707
  2. Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5261